Cognate BioServices is a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapies. We pride ourselves in the level of quality and experience we bring to the table.
Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and bridging into commercial manufacturing. Cognate applies the know-how and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.
Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies, organizations and institutions. Cognate provides a unique combination of custom services to companies across all points of clinical and commercial development ranging from early preclinical studies, to mid phase trials and product scale-up though later stage clinical trials and bridging into commercial manufacturing. Cognate applies the know-how and expertise of its business, scientific and technical teams to successfully develop autologous and allogeneic products across multiple cell-based technology platforms from start to finish.
Location: United States, Tennessee, Memphis
Employees: 201-500
Founded date: 2002
Investors 3
| Date | Name | Website |
| - | Medivate P... | medivatepa... |
| - | LINEA Inve... | lineainves... |
| - | CRG | crglp.com |
Mentions in press and media 7
| Date | Title | Description |
| 27.01.2021 | Cognate BioServices and Nucleus Biologics announce partnership in Cell and Gene Therapies | |
| 15.01.2021 | Cognate doubles manufacturing capacities in Memphis, Europe, as demand for cell and gene therapies skyrockets | The marketplace for gene and cell manufacturing therapeutics continues to be scorching. Cognate BioSciences, a leading CDMO specializing in gene and cell therapy technologies, announced plans Friday that will doubl... |
| 14.01.2021 | Cognate BioServices Announces Major Expansion of Manufacturing Facilities in US and Europe | |
| 20.08.2020 | Cognate BioServices Announces the Appointment of Two Independent Board Members | |
| 28.01.2020 | Cognate BioServices Closes Series B Funding; Acquires Cobra Biologics | Cognate BioServices, a Memphis, Tenn.-based contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products, closed a Series B funding round of undisclosed amount and completed the acqu... |
| 03.09.2019 | New Money: DC-Area Startups Raised $172M of Funding in August | It may have seemed quiet on the District's streets in August, but inside its offices, startups and tech companies were busy making big deals. At least 16 D.C.-area funding deals totaled more than $172 million last month. Leading the list by... |
| 27.08.2019 | Cognate BioServices Closes Growth Capital from EW Healthcare Partners | Cognate BioServices, a Memphis TN-based contract development and manufacturing organization in the global cellular therapies industry, closed on a round of growth capital from EW Healthcare Partners. The amount of the deal was not disclosed... |